Nanomedicines have enormous potential to improve the precision of cancer therapy, yet our ability to efficiently home these materials to regions of disease in vivo remains very limited. Inspired by the ability of communication to improve targeting in biological systems, such as inflammatory-cell recruitment to sites of disease, we construct systems where synthetic biological and nanotechnological components communicate to amplify disease targeting in vivo. These systems are composed of 'signalling' modules (nanoparticles or engineered proteins) that target tumours and then locally activate the coagulation cascade to broadcast tumour location to clot-targeted 'receiving' nanoparticles in circulation that carry a diagnostic or therapeutic cargo, thereby amplifying their delivery. We show that communicating nanoparticle systems can be composed of multiple types of signalling and receiving modules, can transmit information through multiple molecular pathways in coagulation, can operate autonomously and can target over 40 times higher doses of chemotherapeutics to tumours than non-communicating controls.
amplification, positive feedback, ubiquitous presence in plasma and potential to operate across multiple tumour types (Fig. 1c) . We hypothesized that two signalling modules could selectively activate the coagulation cascade in tumours: NPs (gold nanorods, NRs) that target tumours and convert external electromagnetic energy into heat to locally disrupt tumour vessels, and engineered human proteins (tumour-targeted tissue factor, tTF) that autonomously survey host vessels for angiogenic tumour receptors and, in their presence, activate the extrinsic coagulation pathway (Fig. 1c) .
Receiving modules were constructed using two nanomaterial platforms: a prototypical imaging agent (magnetofluorescent iron oxide nanoworms, NWs) and a prototypical therapeutic agent (doxorubicin-loaded liposomes, LPs). We explored the potential to route communication to receivers through two molecular pathways in coagulation by developing peptide coatings that recognize fibrin directly and peptides that target coagulation enzyme activity by acting as a substrate for the coagulation transglutaminase factor XIII (FXIII) (Fig. 1c) .
We first set out to examine the capacity of signalling modules to precisely induce coagulation in tumours (Fig. 2a) . To test our hypothesis that photothermal heating of gold NRs could disrupt tumour blood vessels to initiate extravascular coagulation [19] [20] [21] [22] , we examined the transduction of tumour heating into localized coagulation by evaluating fibrin deposition in tumours as a function a, Schematic representation of communication between system components. Tumour-targeted signalling NPs broadcast the tumour location to receiving NPs in circulation. b, Harnessing a biological cascade to transmit and amplify NP communications. c, Molecular signalling pathway between the signalling and receiving components. Signalling and receiving components act as unnatural inputs and outputs to the coagulation cascade, respectively. Signalling components are either tumour-targeted plasmonic gold NRs, which initiate coagulation cascade activation in tumours by photothermally disrupting tumour vessels and activating the extrinsic and intrinsic coagulation pathways, or tumour-targeted truncated tissue factor proteins, which are latent in circulation and activate the extrinsic coagulation pathway on binding to tumour receptors. Communication is exploited to recruit inorganic (iron oxide nanoworms) or organic (drug-loaded LPs) receiving components through activity of the coagulation transglutaminase FXIII or through targeting of polymerized fibrin.
of temperature (Fig. 2a) . Purified fibrinogen (the precursor to fibrin) and albumin (an abundant blood protein unrelated to coagulation) were labelled with unique near-infrared (NIR) fluorochromes to allow simultaneous assessment of coagulationdependent and independent protein tropism to heated tumours.
Mixtures of fibrinogen and albumin were intravenously injected into athymic (nu/nu) mice bearing bilateral human MDA-MB-435 tumours, after which one tumour was heated using a temperature-controlled water bath. At 24 h, mice were killed and the relative levels of tumour fibrin(ogen) and albumin were assessed fluorescently. We observed a marked induction of fibrin(ogen) accumulation in tumours between 45
• C and 53
• C, with little accompanying increase in albumin accumulation, indicating that heat specifically directed coagulation-cascade activation in tumours (Fig. 2b, Supplementary Fig. S1 ). Immunohistochemical staining for fibrin(ogen) in tumours from uninjected mice corroborated these findings, demonstrating that exogenous fibrinogen administration did not artificially drive accumulation in heated tumours ( Supplementary Fig. S1 ).
Having probed the thermal sensitivity of coagulation in tumours, we next investigated whether tumour-targeted gold NRs could specify coagulation to occur in tumour tissues. Rod-shaped gold NPs are precisely tunable plasmonic nanomaterials that may be synthesized in bulk, have narrow size distributions and have optical absorption coefficients 10 4 -10 6 times higher than those of conventional organic fluorochromes [19] [20] [21] . Previously, we demonstrated that polyethylene glycol-coated gold NRs (PEG-NRs) have >17 h circulation half-lives in mice and can passively target tumours in mice through their fenestrated angiogenic blood vessels to direct precise tumour heating with otherwise benign NIR energy (Supplementary Fig. S2 ; refs [23] [24] [25] . Because NIR light can penetrate several centimetres in human tissue, it provides an attractive external input to actuate vascular disruption in tumours 26 . To examine NR-directed coagulation, PEG-NRs (10 mg Au kg −1 ) or saline were intravenously administered to mice bearing bilateral MDA-MB-435 tumours (Fig. 2c,d ). After PEG-NR clearance from circulation (72 h post-injection), fluorescent fibrinogen was intravenously injected and the right flanks of mice were irradiated with NIR light (∼1 W cm −2 ), generating focal tumour surface temperatures of ∼49
• C in PEG-NR-injected mice, while saline-injected tumour surface temperatures remained below ∼37
• C (Fig. 2c) . At 24 h post-injection, irradiated tumours on NR-injected mice displayed localized accumulation of fibrinogen (Fig. 2d ), while tumours with PEG-NRs or NIR energy alone and peripheral tissues lacked this feature. Histopathological analysis revealed that fibrin(ogen) deposition formed a broad interstitial mesh in heated tumours, indicating that NR heating could disrupt tumour blood vessels to activate extravascular coagulation ( Supplementary Fig. S2 ).
We next investigated the potential for a biological signalling module to autonomously survey the host vasculature for angiogenic tumour receptors and, in their presence, engage the extrinsic coagulation cascade. Such a system would operate without the need for any external electromagnetic inputs (for example NIR energy) and could potentially amplify NP targeting to deep-seated and disseminated cancers. We used a truncated, tumour-targeted version of the human protein tissue factor (tTF-RGD), which harnesses an RGD peptide motif to induce coagulation on binding to angiogenic α v β 3 receptors [27] [28] [29] [30] [31] (Fig. 2e) . When tTF is separated from essential cell surface lipid co-factors, its activity towards FX activation diminishes by five orders of magnitude 32 . This nearly digital dependence on cell-surface localization has enabled tumourtargeted tTFs to specifically activate coagulation in mouse cancer models and, recently, in human cancer patients 27, 28 . As with PEG-NR signalling modules, we first probed the relative accumulation of fluorescently labelled fibrinogen and albumin in MDA-MB-435 tumours of mice injected with varying doses of tTF-RGD proteins. At 24 h after injection, we observed a macroscopic appearance of haemorrhage in tumours on mice injected with tTF-RGD (>15 µg tTF-RGD/mouse), corresponding to the tumour-specific accumulation of fibrinogen in dendritic, vascular patterns, which were absent from control tumours (Fig. 2f,g, Supplementary Fig.  S3 ). Microscopically, this appearance of vascular coagulation was corroborated by the abundant localization of fibrin(ogen) within tumour blood vessels (Fig. 2g) .
Together, we found that both PEG-NR and tTF-RGD signalling modules produced tumour-specific coagulation, highlighting the potential for localized coagulation to communicate the tumour's location to receivers in circulation. We next set out to develop receiving NPs that could efficiently target regions of coagulation to deliver therapeutics or act as imaging agents (Fig. 3a) . Initially, magnetofluorescent iron oxide nanoworm imaging agents (NWs; Fig. 3b top) were derivatized with a peptide substrate for the coagulation transglutaminase [33] [34] [35] to enable receiver incorporation into regions of active coagulation ( Fig. 3b bottom, Supplementary  Fig. S4 ). Having observed that external heating of tumours produced localized coagulation, we used this response in an assay to assess the ability of receivers to target tumour coagulation before integrating them with signalling modules. Mixtures of targeted and untargeted NWs, labelled with unique NIR fluorochromes, were intravenously injected into mice bearing two MDA-MB-435 tumours. Immediately following injection, one tumour was submerged in a temperature-controlled water bath for 20 min and mice were dissected at 24 h for fluorescent organ imaging. We found that the accumulation of FXIII-NW receivers was sharply amplified at 45
• C compared with FXIIIControl-NW-bearing peptides without the essential glutamine for FXIII cross-linking (Fig. 3c,d , Supplementary Fig. S5 ), enabling nearly an order-ofmagnitude increase in tumour targeting compared with unheated tumours. The specificity of heat-induced targeting to coagulation persisted up to 53
• C, although the magnitude of accumulation decreased (Fig. 3e) , probably indicating that higher temperatures accelerated intravascular coagulation and occlusion, diminishing the perfusion required for delivery of receiving NWs into tumours. Histopathologically, FXIII-NWs showed marked extravasation and interstitial spreading in heated tumours compared with controls ( Fig. 3d, Supplementary Fig. S5 ), illustrating the capacity of thermal energy to dismantle tumour vascular barriers and direct abundant interstitial receiver accumulation.
We also explored the feasibility of channelling communications through an alternative molecular pathway in the coagulation cascade. NWs were derivatized with a fibrin-binding peptide ( Fig. 3b ) and tested in a similar assay. Fibrin-binding receiving NWs also exhibited nearly a tenfold amplification of targeting to heated tumours (Fig. 3c, Supplementary Fig. S5 ), with prominent extravascular accumulation histopathologically (Supplementary Fig. S5) .
We next constructed model therapeutic receiving modules to provide amplified drug delivery to regions of tumour Receiving modules: coagulation. Therapeutic receivers were developed by synthesizing doxorubicin-loaded LPs with tethered active (FXIII) or inactive (FXIIIControl) substrates (Supplementary Figs S4, S6) . Here, tumour heating to 45
• C directed the accumulation of over 40 times higher doses of doxorubicin in tumours compared with unheated controls and significantly enhanced targeting over inactive FXIIIControl substrate-modified LPs (Fig. 3f) .
Having developed signalling and receiving modules and characterized their functions in isolation, we proceeded to study the ability of integrated NP systems to communicate and amplify tumour targeting in vivo (Fig. 4a) . We began by testing the ability for communication to amplify the targeting of magnetofluorescent FXIII-NW receiving modules to tumours. PEG-NRs (or saline) were intravenously injected into mice bearing bilateral MDA-MB-435 tumours. After NR clearance from circulation (72 h), mixtures of active and inactive receiving NPs (FXIII-NWs and FXIIIControl-NWs) labelled with distinct NIR fluorochromes were co-injected intravenously, followed by NIR irradiation of the entire right flank of the mouse (∼0.75 W cm −2 , 810 nm, 20 min) under infrared thermographic observation. At 96 h, the entire mouse and then the individual explanted organs were fluorescently imaged (Fig. 4b) . Thermographic surveillance of photothermal heating showed focal tumour heating only in NR-injected mice (Fig. 4c) and whole-animal imaging at 96 h revealed pronounced homing of FXIII-NWs to NR-heated tumours, with over an order-of-magnitude increase in accumulation above unirradiated contralateral tumours and tumours on saline-injected mice (Fig. 4d,e, Supplementary Fig. S7 ). Histologically, integrated NP systems produced intense regions of FXIII-NW fluorescence relative to controls, particularly in tumour boundaries where blood vessels were well perfused ( Supplementary Fig. S8 ). NP systems were found to be effective in xenograft cervical tumour models as well, directing several-fold amplification in homing of targeted receiving NPs over untargeted controls (Supplementary Fig. S9 ).
We next probed the ability of autonomous communication between tTF-RGD signalling modules and FXIII-NW receiving modules to amplify tumour targeting (Fig. 4f) . When co-injected alongside FXIII-NW receivers (Fig. 4g) , we find that tTF-RGD signalling modules amplify receiver targeting by several-fold over non-communicating controls and over NWs that are directly targeted by RGD-targeting ligands (Fig. 4h, Supplementary  Fig. S10 ). Similar to the fibrin(ogen) distribution observed during tTF-RGD signalling-module testing, FXIII-NW receivers injected alongside tTF-RGD proteins produced a dendritic pattern of accumulation in tumours, corresponding to abundant intravascular localization immunohistochemically (Fig. 4h-j) . This amplified vascular targeting was found to be specific for tumours over normal organs and was absent when the coagulation inhibitor heparin was administered alongside signalling and receiving modules (Fig. 4i, Supplementary Fig. S10 ). Further, we found that tTF-NGR signalling modules, which target CD13 angiogenic receptors, were also able to amplify receiver targeting to tumours (Supplementary Fig. S10 ), highlighting the capacity for autonomously communicating systems to be customized for specific molecular cancer signatures.
As a proof of principle that NP communication could improve tumour drug delivery and therapy, we studied the efficacy of a therapeutic communicating nanosystem (Fig. 5a) . We found that communication between NR signalling modules and FXIII-LP receivers amplified the accumulation of doxorubicin in tumours by over 40-fold (∼8% ID g −1 ) as compared with the LPs alone (Fig. 5b) and more than sixfold when compared with an optimized LP formulation that targeted endogenous vascular receptors (α v β 3 for high-affinity cyclic-RGD peptide-targeted LPs), illustrating the potential for NP communication to amplify drug delivery over NPs directly targeted to tumour receptors ( Supplementary Fig. S11 ). This amplification of drug delivery probably has at least two components: heat-dependent increases in passive accumulation due to improved extravasation in tumours (as indicated by FXIIIControl-LPs and consistent with previous observations 22 ) and specific biochemical recognition of the coagulation process by the peptide coating. Histologically, FXIII-LPs formed a broad interstitial mesh in NR-heated tumours, with released doxorubicin fluorescence emanating from the nuclei of surrounded tumour cells, confirming the delivery and release of active drug within tumour tissues (Fig. 5c) .
We finally evaluated the therapeutic efficacy of communicating NPs in mice bearing single MDA-MB-435 human carcinoma tumours. PEG-NRs (10 mg kg −1 ) or saline were injected into mice and, once NRs had cleared from circulation (72 h), a single intravenous dose of FXIII-LPs, FXIIIControl-LPs or saline (2 mg kg −1 doxorubicin) was given, followed immediately by irradiation with NIR energy (∼0.75 W cm −2 , 810 nm, 20 min). We found that a single treatment with communicating NPs directed a prolonged inhibition of tumour growth that was significantly more effective than system components in isolation (FXIII-LPs, FXIIIControl-LPs, NRs) and non-communicating control systems (NRs + FXIIIControl-LPs; Fig. 5d ,e; p < 0.05 for NR + FXIII-LPs compared with all other treatment groups at each day from 5 to 24 after treatment; one-sided t -test) without detectable weight loss due to systemic toxicity ( Supplementary Fig. S11 ).
Inspired by communication in biological systems, we devised NP systems that communicate to amplify tumour targeting. We demonstrated that systems of synthetic human proteins and simple NPs can be engineered to transmit information through endogenous biological pathways by acting as artificial inputs and outputs to the coagulation cascade. In contrast with 'combination' therapies, where multiple disease pathways in the host are targeted simultaneously, our strategy was composed of components that communicate with one another to more efficiently target regions of disease. We found that communication through the coagulation cascade enhanced the accumulation of receiving modules in tumours by up to 40-fold relative to receiving modules tested in the absence of communication (Supplementary Fig. S12 ). Further, we found that, after subtracting the baseline targeting of receivers without communication, each NR signalling module in a host tumour was able to recruit more than 150 FXIII-NWs or more than 35,000 doxorubicin molecules encapsulated within FXIII-LPs (Supplementary Fig. S12 ), demonstrating the capacity for signal amplification in our approach. Similarly, each tTF-RGD signalling module that accumulated in a host tumour was able to recruit more than ten FXIII-NWs through induction of localized coagulation (Supplementary Fig. S12 ). The ability for each tumour-receptor-targeted tTF-RGD signalling module in our system to recruit many NP receiving modules contrasts to conventional strategies for ligandmediated NP targeting, where, depending on NP valency, one or fewer NPs are delivered per ligand-bound receptor in tumours.
We believe that this work motivates a paradigm of 'systems nanotechnology' directed toward the construction of communicative diagnostic and therapeutic agents with sophisticated in vivo behaviours. Given the diverse NP and synthetic biological 'building blocks' under development [13] [14] [15] [16] [17] [18] [36] [37] [38] , coupled with the plethora of robust biological cascades that could be re-purposed to enable communication between synthetic components, we believe that a wide array of nanosystems could be engineered to more sensitively locate, diagnose and treat a diversity of focal human diseases.
Methods
Signalling-module synthesis. Long-circulating PEG-NRs were synthesized with 5 kDa methoxy PEG-thiol coatings as described previously 23 and tTF-RGD and tTF-NGR signalling modules were expressed in engineered Escherichia coli, purified and tested in vitro to verify purity (>95%) and activity (factor-X coagulation test) as described in Supplementary Information.
Receiving-module synthesis. Peptide synthesis. The three peptides used in this work were synthesized through 9-fluorenyl-methoxycarbonyl solid-phase peptide synthesis, purified by high-performance liquid chromatography to >90% purity, and characterized through mass spectrometry as described in Supplementary Information.
Iron oxide NW synthesis. Superparamagnetic, dextran-caged iron oxide NWs with a longitudinal size of ∼55 nm were synthesized, aminated using 20% v/v ammonium hydroxide, and derivatized with NIR fluorophores as described previously 11 . All peptide-functionalized NWs were characterized through dynamic light scattering and intravenously injected in vivo to ensure all targeted NWs and control NWs exhibited similar circulation times. NIR-fluorophore and peptide attachment protocols, along with NW purification methods, are provided in Supplementary Information. Doxorubicin-loaded LP synthesis. Hydrogenated soy sn-glycero-3-phosphocholine (HSPC), cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N -polyethylene glycol 2000 (DSPE-PEG(2k)) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol 2000)] (DSPE-PEG(2k)-MAL) were purchased from Avanti Polar Lipids. Doxorubicin was purchased from Sigma Chemical. Briefly, for targeted LP synthesis, LPs with maleimide groups were prepared from HSPC, cholesterol, DSPE-PEG(2k) and DSPE-PEG(2k)-MAL by lipid film hydration and membrane extrusion. Encapsulation of doxorubicin into the LPs was then carried out using a pH-gradient-driven loading protocol. Free doxorubicin was removed by gel filtration on Sephadex G-50 and the maleimide-terminated LPs were reacted with thiols on peptides (FXIII and FXIIIControl) for 2 h and then purified by gel filtration.
In vivo studies. All studies in mice were approved by the Massachusetts Institute of Technology Committee on Animal Care. MDA-MB-435 human cancer cells were cultured as recommended by the American Type Culture Collection and injected into nu/nu mice to establish xenograft tumours as described previously 3, 11, 23 . Signalling-module distribution and bioactivity in vivo. Signalling-module biodistribution and fibrinogen coagulation assays are provided in Supplementary Information.
Immunohistochemical analysis in tumours. For histologic analysis, frozen sections of tumours were prepared. The sections were first fixed with acetone. Rat anti-mouse CD-31 (1:50, BD PharMingen) and biotinylated mouse fibrin(ogen) antiserum (1:50, Nordic) were used for immunochemical staining of tumour tissue sections. The corresponding secondary antibodies were added and incubated for 1 h at room temperature: AlexaFluor-594 goat anti-rat or rabbit IgG (1:1,000; Molecular Probes) and streptavidin Alexa Fluor 594 (1:1,000; Molecular Probes). The slides were washed three times with PBS and mounted in Vectashield Mounting Medium with 4,6-diamidino-2-phenylindole. At least three images from representative microscopic fields were analysed for each tumour sample.
Imaging receiving-NW homing to tumours. Mixtures of NIR-fluorophore-labelled, targeted and control NWs (bearing VT750 and VT680 or VT680 and VT750, respectively) were co-administered intravenously in PBS (2 mg Fe kg −1 ) to tumour-bearing nu/nu mice to provide an internal control reference for coagulation-specific NW homing. At 24 h post NW injection, mice were killed and organs were analysed for both NIR fluorophores (LI-COR Odyssey Infrared Imaging System). For integrated NP-system characterization, mice were additionally imaged under isofluorane anaesthetic before killing using a whole-animal fluorescence reflectance imaging system (Xenogen, IVIS Imaging System) to visualize the specificity of NW homing to tumours. Images from both organ scanning and whole-animal imaging are displayed throughout the manuscript as overlaid green-red images from both fluorescence channels (VT750 = green and VT680 = red). For autonomously communicating nanosystems, NIR-fluorophore-labelled peptide-bearing NWs (bearing VT750 fluorophores) were intravenously (2 mg Fe kg −1 ) in PBS to unanaesthetized MDA-MB-435 tumour-bearing nu/nu mice alone or alongside various tTF signalling modules (25 µg). At 24 h post NW injection, mice were killed and organs were analysed for NIR-receiver fluorescence (LI-COR Odyssey Infrared Imaging System). For intraoperative fluorescent tumour imaging, mice were anaesthesized and tumours were surgically exposed to reveal detailed tumour fluorescence (LI-COR). For whole-animal organ distribution, tTF-RGD signalling modules were administered intraperitoneally (25 µg) and FXIII-NWs were administered intravenously (2 mg Fe kg −1 ) to mice bearing a single MDA-MB-435 tumour.
Quantification of receiver homing to tumours. Protocols for fluorescent quantification of NW and doxorubicin quantification are provided in Supplementary Information.
Therapeutic assessment of communicating and control NP systems. Therapeutic studies were conducted by first intravenously administering PEG-NRs or saline into nu/nu mice bearing a single MDA-MB-435 tumour. At 72 h post-injection, mice were intravenously administered FXIII-LPs, FXIIIControl-LPs or saline (in a ∼150 µl bolus) and broadly irradiated in the vicinity of the tumour with NIR light (810 nm, ∼1 W cm −2 , 20 min). An additional cohort of mice was administered saline at 0 and 72 h and not exposed to NIR light to isolate any therapeutic efficacy of this input in isolation. At regular intervals after treatment, tumours were measured and mice were weighed. Mice were killed when tumours exceeded 500 mm 3 .
